SCHEMBL30760419

SCHEMBL30760419

CC(C)(C)OC(=O)Nc1ncc(S(=O)(=O)Cl)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
FFAR2 O15552 1/20 0.43
CCNE2 O96020 3/20 0.41
CCNE1 P24864 3/20 0.41
CDK2 P24941 3/20 0.41
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CDK4 P11802 1/20 0.41
CCNB1 P14635 1/20 0.41
CCND1 P24385 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41
LCK P06239 6/20 0.40
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ATR Q13535 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL540577 0.79 CCNE1 (0.43) CA1CA2FFAR2CCNE2CCNE1
SCHEMBL12241503 0.78 RAB9A (0.52) CA1CA2CCNE2CCNE1CDK2
SCHEMBL27174909 0.77 FFAR2 (0.40) FFAR2CCNE2CCNE1CDK2ALDH1A1
SCHEMBL1984390 0.77 CA1 (0.45) CA1CA2CCNE2CCNE1CDK2
SCHEMBL27819346 0.77 CA1 (0.47) CA1CA2CCNE2CCNE1CDK2
SCHEMBL20877512 0.77 CA1 (0.47) CA1CA2FFAR2CCNE2CCNE1
SCHEMBL640631 0.77 FFAR2 (0.52) CA1CA2FFAR2CCNE2CCNE1
SCHEMBL13266901 0.77 CA1 (0.47) CA1CA2CCNE2CCNE1CDK2
SCHEMBL13039 0.77 FPR3 (0.54) CA1CA2FFAR2CCNE2CCNE1
SCHEMBL15921777 0.77 CA1 (0.50) CA1CA2CCNE2CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116874-A1 HETEROAROMATIC INDOLESULFONAMIDES SEED THERAPEUTICS INC (US) 2026-04-30 US disclosed
EP-4704836-A1 HETEROAROMATIC INDOLESULFONAMIDES Seed Therapeutics, Inc (US) 2026-03-11 EP disclosed
EP-4573088-A1 HETEROCYCLE RBM39 MODULATORS Recursion Pharmaceuticals, Inc. (US) 2025-06-25 EP disclosed
WO-2024229040-A1 HETEROAROMATIC INDOLESULFONAMIDES SEED THERAPEUTICS, INC (US) 2024-11-07 WO disclosed
US-20240092770-A1 Heterocycle RMB39 Modulators RECURSION PHARMACEUTICALS, INC. 2024-03-21 US disclosed
WO-2024039689-A1 HETEROCYCLE RBM39 MODULATORS RECURSION PHARMACEUTICALS, INC. (US) 2024-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116874-A1 HETEROAROMATIC INDOLESULFONAMIDES DCAF1, DCAF15, DDX39B CA1 4403/4885CA2 4517/4885FFAR2 4315/4885
US-20240092770-A1 Heterocycle RMB39 Modulators PRMT9, RCC2, RBBP9 CA1 4867/4885CA2 4825/4885FFAR2 4503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.